PICO Advisory Sub-Committee – Applications Considered
- 1573 - Reproductive carrier screening for fragile X syndrome, spinal muscular atrophy and cystic fibrosis (2nd consideration)
- 1582 - Detection of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibody antibodies for diagnosis of neuromyelitis opticaand myelin oligodendrocyte glycoprotein antibody-related demyelination
- 1585 - Genetic testing for the diagnosis of early-onset or familial neuromuscular disorders
- 1595 - Closed loop upper airway stimulation for moderate to severe obstructive sleep apnoea, in patients who have failed or are intolerant to continuous positive airway pressure therapy
- 1597 - Cryoablation for small renal mass
- 1598 - Genetic testing for diagnosis of inheritable cardiac rhythm disorders
- 1599 - Gentesting for the diagnosis of cardiomyopathies
- 1600 - Genetic testing for inherited kidney disease (other than Alport syndrome)
- 1602 - Testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusion status, in patients with locally advanced or metastatic solid tumours, to determine eligibility for larotrectinib
- 1603 - Transcatheter aortic valve implantation (TAVI) via transfemoral delivery, using the SAPIEN 3 balloon-expandable valve system, for patients at intermediate risk for surgery
- 1604 - PIK3CA mutation testing for postmenopausal women or men with advanced breast cancer who have progressed during or following treatment with an aromatase inhibitor
- 1605 - Transcatheter delivery of a dual-filter cerebral embolic protection system during transcatheter aortic valve implantation